Business Context and Reporting Period
This Form 8-K, dated June 7, 2021, is filed by HighCape Capital Acquisition Corp. (the "Company") regarding its proposed business combination with Quantum-Si Inc. The filing serves as a voluntary supplement to the Definitive Proxy Statement/Prospectus following the receipt of demand letters from purported shareholders. The Company's S-4 registration statement was declared effective by the SEC on May 14, 2021, with a special meeting of stockholders scheduled for June 9, 2021, to vote on the transaction.
Key Financial Metrics and Transaction Details
The filing does not contain specific revenue, profit, cash flow, or debt metrics for HighCape or Quantum-Si. Instead, it provides valuation multiples for comparable companies used in the transaction analysis:
- Comparable Company Multiples (EV/2023E Revenue): Ranges from 10.2x (Nano-X Imaging) to 145.5x (Nautilus Biotechnology).
- Comparable Company Growth (EV/2021-2024E Revenue CAGR): Ranges from 13.9% (Illumina) to 338.7% (Nautilus Biotechnology).
- PIPE Financing: J.P. Morgan was retained as a placement agent for the Private Investment in Public Equity (PIPE) transaction. Fees are contingent on the closing of the PIPE and/or the Business Combination.
Material Changes and Supplemental Disclosures
The filing amends the Definitive Proxy Statement/Prospectus with the following material updates:
- Advisory Fees: Disclosure added regarding J.P. Morgan's expanded role from placement agent to merger and acquisitions advisor, with fees contingent on transaction closing.
- Board Composition: Confirmation that Mr. Kevin Rakin agreed to join the board of the post-business combination company.
- Valuation Data: Specific enterprise value and growth rate multiples for seven comparable biotechnology and life sciences companies were added as footnotes to the valuation chart.
Guidance, Risks, and Management Commentary
Management Commentary: HighCape and its board of directors state that the allegations in the shareholder demand letters lack merit. The supplemental disclosures are being made voluntarily to avoid delays, minimize costs, and reduce uncertainties associated with defending the claims. The Company explicitly denies any liability or wrongdoing.
Risks and Contingencies: The primary risk identified is the potential for shareholder litigation to delay or adversely affect the Business Combination. The filing notes that the supplemental information supersedes conflicting information in the original proxy statement.
Investor Verification Checklist
- Verify the final vote results from the special meeting scheduled for June 9, 2021.
- Confirm the final terms and closing status of the PIPE financing with J.P. Morgan.
- Review the full Definitive Proxy Statement/Prospectus (File No. 333-253691) for complete financial projections of Quantum-Si, as this 8-K only contains supplemental valuation data.
- Monitor for any updates regarding the shareholder demand letters and potential litigation outcomes.